Mereo BioPharma Group plc (MREO) has gained over 160% in the last three trading days as it gears up for a couple of important clinical trial catalysts in the coming year.
The Company's lead drug candidate is Setrusumab, a potential treatment for osteogenesis imperfecta, also known as brittle bone disease. Setrusumab was acquired from Novartis in 2015.
Osteogenesis imperfecta, or OI, is a rare genetic disorder characterized by bone fragility leading to fracture and bone deformity, chronic bone pain and reduced mobility. (Source: NCBI). An estimated 20,000 to 50,000 people in the United States have osteogenesis imperfecta, according to reports. To date, there are no approved treatments for OI.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.